MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 341058 | Name: Clocapramine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Clocapramine is an atypical antipsychotic of the imidobenzyl.

Chemical Structure

Clocapramine
Clocapramine
CAS#47739-98-0 (free base)

Theoretical Analysis

MedKoo Cat#: 341058

Name: Clocapramine

CAS#: 47739-98-0 (free base)

Chemical Formula: C28H37ClN4O

Exact Mass: 480.2656

Molecular Weight: 481.08

Elemental Analysis: C, 69.91; H, 7.75; Cl, 7.37; N, 11.65; O, 3.33

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
60789-62-0 (HCl) 47739-98-0 (free base)
Synonym
Clocapramine; Y 4153; Y-4153; Y4153.
IUPAC/Chemical Name
1'-(3-(3-Chloro-10,11-dihydro-5H-dibenz(b,f)azepin-5-yl)propyl)(1,4'-bipiperidine)-4'-carboxamide
InChi Key
QAZKXHSIKKNOHH-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H37ClN4O/c29-24-12-11-23-10-9-22-7-2-3-8-25(22)33(26(23)21-24)18-6-15-31-19-13-28(14-20-31,27(30)34)32-16-4-1-5-17-32/h2-3,7-8,11-12,21H,1,4-6,9-10,13-20H2,(H2,30,34)
SMILES Code
c1ccc2c(c1)CCc3ccc(cc3N2CCCN4CCC(CC4)(C(=O)N)N5CCCCC5)Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 481.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kishi T, Ikuta T, Matsunaga S, Matsuda Y, Oya K, Iwata N. Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population. Neuropsychiatr Dis Treat. 2017 May 11;13:1281-1302. doi: 10.2147/NDT.S134340. eCollection 2017. PubMed PMID: 28553116; PubMed Central PMCID: PMC5439983. 2: Kishi T, Matsunaga S, Matsuda Y, Iwata N. Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine. Neuropsychiatr Dis Treat. 2014 Dec 10;10:2339-51. doi: 10.2147/NDT.S73464. eCollection 2014. PubMed PMID: 25525363; PubMed Central PMCID: PMC4266422. 3: Saito M, Miyaoka H. Augmentation of paroxetine with clocapramine in panic disorder. Psychiatry Clin Neurosci. 2007 Aug;61(4):449. PubMed PMID: 17610675. 4: Oka T, Hamamura T, Lee Y, Miyata S, Habara T, Endo S, Taoka H, Kuroda S. Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain. Life Sci. 2004 Nov 26;76(2):225-37. PubMed PMID: 15519367. 5: Koreeda A, Yonemitsu K, Ng'walali PM, Muraoka N, Tsunenari S. Clocapramine-related fatality. Postmortem drug levels in multiple psychoactive drug poisoning. Forensic Sci Int. 2001 Oct 15;122(1):48-51. PubMed PMID: 11587865. 6: Schotte A, Bonaventure P, Janssen PF, Leysen JE. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used. Jpn J Pharmacol. 1995 Dec;69(4):399-412. PubMed PMID: 8786644. 7: Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, Yokogawa K. Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy. Neuropsychopharmacology. 1995 Feb;12(1):57-64. PubMed PMID: 7766287. 8: Morio Y, Tanimoto H, Yakushiji T, Morimoto Y. Characterization of the currents induced by sigma ligands in NCB20 neuroblastoma cells. Brain Res. 1994 Feb 21;637(1-2):190-6. PubMed PMID: 7910100. 9: Uchihashi Y, Morimoto T, Tadokoro S. [Effects of mosapramine (Y-516), a new dopamine D2 antagonist, on reverse tolerance after repeated administration of methamphetamine by means of the ambulation-increasing effect in mice]. Nihon Yakurigaku Zasshi. 1992 Mar;99(3):153-60. Japanese. PubMed PMID: 1505855. 10: Morimoto T, Morimoto Y, Fukuda T, Setoguchi M. [Effect of Y-516 on the hyperactivity induced by dopamine injected bilaterally into the nucleus accumbens]. Nihon Yakurigaku Zasshi. 1990 Aug;96(2):65-71. Japanese. PubMed PMID: 2227720. 11: Ishigooka J, Murasaki M, Wakatabe H, Miura S, Hikida K, Shibata M, Nobunaga H. Pharmacokinetic study of iminodibenzyl antipsychotic drugs, clocapramine and Y-516 in dog and man. Psychopharmacology (Berl). 1989;97(3):303-8. PubMed PMID: 2566185. 12: Yamagami S, Kiriike N, Kawaguchi K. A single-blind study of clocapramine and sulpiride in hospitalized chronic schizophrenic patients. Drugs Exp Clin Res. 1988;14(11):707-13. PubMed PMID: 3246215. 13: Suzuki O, Hattori H, Asano M, Brandenberger H. Positive and negative ion mass spectrometry of tricyclic antidepressants. Z Rechtsmed. 1986;97(4):239-50. PubMed PMID: 3577433. 14: Mikuni M, Yamashita I, Matsubara S, Odagaki Y, Setoguchi M, Fukuda T. Pharmacological and biochemical properties of iminodibenzyl antipsychotic drugs including Y-516 and clocapramine. Clin Neuropharmacol. 1986;9 Suppl 4:319-21. PubMed PMID: 2882844. 15: Fukuda T, Setoguchi M, Morimoto Y, Shoji H, Tsumagari T, Maruyama Y. [Neuroleptic properties of Y-516, a new iminodibenzyl derivative]. Nihon Yakurigaku Zasshi. 1985 Sep;86(3):197-208. Japanese. PubMed PMID: 2867957. 16: Setoguchi M, Sakamori M, Takehara S, Fukuda T. Effects of iminodibenzyl antipsychotic drugs on cerebral dopamine and alpha-adrenergic receptors. Eur J Pharmacol. 1985 Jun 19;112(3):313-22. PubMed PMID: 2862053. 17: Yamagami S. A crossover study of clocapramine and haloperidol in chronic schizophrenia. J Int Med Res. 1985;13(6):301-10. PubMed PMID: 4076529. 18: Tsukamoto T, Asakura M, Hirata N, Imafuku J, Matsui H, Hasegawa K. Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. PubMed PMID: 6149771. 19: Fukuda T, Tsumagari T. [Effects of psychotropic drugs on lateral hypothalamic self-stimulation behavior in rats: correlation between self-stimulation behavior inhibition and striatal dopaminergic blockade by neuroleptic drugs]. Nihon Yakurigaku Zasshi. 1984 Jun;83(6):485-96. Japanese. PubMed PMID: 6149172. 20: Nakazawa T, Ohara K, Sawa Y, Edakubo T, Matsui H, Sawa J, Kawaguchi K, Hattori S, Nakajima M. Comparison of efficacy of timiperone, a new butyrophenone derivative, and clocapramine in schizophrenia: a multiclinic double-blind study. J Int Med Res. 1983;11(5):247-58. PubMed PMID: 6139317.